雅各臣科研製藥(02633.HK)擬4623萬港元收購李眾勝堂(集團)約10萬股
格隆匯11月11日丨雅各臣科研製藥(02633.HK)及健倍苗苗(02161.HK)公吿，於2024年11月11日，健倍苗苗的間接全資附屬公司Po Chai Herbal及健倍苗苗的間接全資附屬公司PCHT(作為賣方)與雅各臣的間接全資附屬公司歐化藥業(作為買方)訂立買賣協議，據此，Po Chai Herbal及PCHT有條件同意分別出售56,500股及44,000股銷售股份，而歐化藥業有條件同意收購有關李眾勝堂(集團)有限公司的100,500股股份，總代價為4623萬港元(即每股銷售股份460港元)。
自2007年起，歐化藥業向科技園租賃大埔創新園的若干土地及建築物(統稱"工廠")用作製造藥品。在該租賃("科技園租賃")下，歐化藥業可於科技園事先書面批准下，許可若干實體使用工廠。該等實體包括(i)歐化藥業的附屬公司；(ii)其持有超過20%股份的歐化藥業聯營公司；(iii)同一母公司下的歐化藥業同系附屬公司；(iv)歐化藥業的關連公司，前提是其50%股份由與歐化藥業相同的最終實益擁有人擁有，但並非同系附屬公司；(v)歐化藥業的母公司。該等實體統稱為"獲許可實體"。
自2013年起，歐化藥業已向目標公司許可使用工廠的未使用部分，讓其能夠就製造品牌中藥建立符合藥品生產質量管理規範的生產設施。科技園已批准該安排，原因為目標公司為歐化藥業同系附屬公司，因而屬科技園租賃下的獲許可實體。
然而，於2023年分派健倍苗苗股份後，健倍苗苗不再為雅各臣的附屬公司，而雅各臣亦不再持有目標公司的間接權益。由於目標公司目前並非科技園租賃下的獲許可實體，科技園表示除非目標公司成為獲許可實體，否則其將不會批准重續許可。
為解決此問題，訂約方協定訂立買賣協議，據此，歐化藥業將收購目標公司已發行股份的20.1%，此舉使目標公司成為歐化藥業的聯營公司，從而成為科技園租賃下的獲許可實體。買賣協議經公平磋商後訂立，當中考慮目標公司的過往財務表現、財務狀況以及本節所述的理由及裨益。
該許可安排為歐化藥業帶來未使用工廠空間的租金收入，亦為目標公司提供合適製造場地。搬遷目標公司現有符合藥品生產質量管理規範的設施成本高昂及費時，故該等交易讓目標公司在毋須中斷營運的情況下繼續營運，亦避免搬遷開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
